Dornase Alfa Administered to Patients With COVID-19 (DACOVID)

Completed

Conditions studied: COVID-19, Mechanical Ventilation

In brief

Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with severe COVID-19-acting as a mucolytic and targeting NETs.

Key facts

Study ID

NCT04387786

Run by

Feinstein Institute for Medical Research

People needed

5

Starts

2020-03-31

Expected to finish

2020-09-04

Last updated by the study team

2020-11-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• mechanically ventilated patients with COVID-19

You may not qualify if…

• healthy, non-ventilated

Where it is running

• Feinstein Insitute for Medical Research at Northwell Health — Manhasset, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.